Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma / 南方医科大学学报
Journal of Southern Medical University
; (12): 460-462, 2008.
Article
in Zh
| WPRIM
| ID: wpr-293353
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the feasibility and efficacy of radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab (131 I-anti-HBsAg Fab) combined with 131 I-labeled anti-nucleus antigen monoclonal antibody chTNT (131 I-chTNT) in nude mice bearing human hepatocellular carcinoma.</p><p><b>METHODS</b>Nude mice bearing subcutaneous human hepatocellular carcinoma xenografts were treated by intratumoral injection of 131 I-anti-HBsAg Fab and/or 131 I-chTNT, and the changes in the tumor size and alterations in the radioactivity concentration in the tumor and non-tumor tissues were observed.</p><p><b>RESULTS</b>The tumor inhibition rate in mice treated with 131 I-anti-HBsAg Fab combined with 131 I-chTNT (73.09%) was significantly higher than that in mice treated with 131 I-anti-HBsAg Fab (47.8%) or 131 I-chTNT (54.26%) alone. Combined treatment also resulted in significantly higher tumor-to-normal radioactivity concentration ratios than the treatment with the single agents.</p><p><b>CONCLUSION</b>Intratumoral injection with 131 I-labeled monoclonal antibodies can increase the radioactivity concentration in the tumor and enhance the efficacy of the radioimmunotherapy in nude mice bearing human hepatocellular carcinoma.</p>
Full text:
1
Index:
WPRIM
Main subject:
Pathology
/
Radiotherapy
/
Immunoglobulin Fab Fragments
/
Antibodies, Antinuclear
/
Treatment Outcome
/
Radioimmunotherapy
/
Carcinoma, Hepatocellular
/
Immunoconjugates
/
Xenograft Model Antitumor Assays
/
Cell Line, Tumor
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
Zh
Journal:
Journal of Southern Medical University
Year:
2008
Type:
Article